These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 33606809)
21. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women. Zeng C; Guo X; Wen W; Shi J; Long J; Cai Q; Shu XO; Xiang Y; Zheng W Breast Cancer Res Treat; 2020 Jun; 181(2):465-473. PubMed ID: 32318955 [TBL] [Abstract][Full Text] [Related]
23. Detection of germline variants in Brazilian breast cancer patients using multigene panel testing. Guindalini RSC; Viana DV; Kitajima JPFW; Rocha VM; López RVM; Zheng Y; Freitas É; Monteiro FPM; Valim A; Schlesinger D; Kok F; Olopade OI; Folgueira MAAK Sci Rep; 2022 Mar; 12(1):4190. PubMed ID: 35264596 [TBL] [Abstract][Full Text] [Related]
24. Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing. Tuncer SB; Celik B; Erciyas SK; Erdogan OS; Gültaslar BK; Odemis DA; Avsar M; Sen F; Saip PM; Yazici H Pathol Res Pract; 2024 Feb; 254():155075. PubMed ID: 38219492 [TBL] [Abstract][Full Text] [Related]
25. Validation of a next generation sequencing assay for BRCA1, BRCA2, CHEK2 and PALB2 genetic testing. Sim WC; Lee CY; Richards R; Bettens K; Mottier V; Goh LL Exp Mol Pathol; 2020 Oct; 116():104483. PubMed ID: 32531196 [TBL] [Abstract][Full Text] [Related]
26. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic. Riedlova P; Janoutova J; Hermanova B Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084 [TBL] [Abstract][Full Text] [Related]
27. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer. Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241 [TBL] [Abstract][Full Text] [Related]
28. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer. Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628 [TBL] [Abstract][Full Text] [Related]
29. Ethnicity-specific BRCA1, BRCA2, PALB2, and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus. Sokolenko AP; Bakaeva EK; Venina AR; Kuligina ES; Romanko AA; Aleksakhina SN; Belysheva YV; Belogubova EV; Stepanov IA; Zaitseva OA; Yatsuk OS; Togo AV; Khamgokov ZM; Kadyrova AO; Pirmagomedov AS; Bolieva MB; Epkhiev AA; Tsutsaev AK; Chakhieva MD; Khabrieva KM; Khabriev IM; Murachuev MA; Buttaeva BN; Baboshkina LS; Bayramkulova FI; Katchiev IR; Alieva LK; Raskin GA; Orlov SV; Khachmamuk ZK; Levonyan KR; Gichko DM; Kirtbaya DV; Degtyariov AM; Sultanova LV; Musayeva HS; Belyaev AM; Imyanitov EN Breast Cancer Res Treat; 2024 Jan; 203(2):307-315. PubMed ID: 37851290 [TBL] [Abstract][Full Text] [Related]
30. Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients. Gomes R; Spinola PDS; Brant AC; Matta BP; Nascimento CM; de Aquino Paes SM; Bonvicino CR; Dos Santos ACE; Moreira MAM Breast Cancer Res Treat; 2021 Feb; 185(3):851-861. PubMed ID: 33128190 [TBL] [Abstract][Full Text] [Related]
32. Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis. Theobald KA; Susswein LR; Marshall ML; Roberts ME; Mester JL; Speyer D; Williams RNW; Knapke SC; Solomon SR; Murphy PD; Klein RT; Hruska KS; Solomon BD Ann Surg Oncol; 2018 Nov; 25(12):3556-3562. PubMed ID: 30167906 [TBL] [Abstract][Full Text] [Related]
33. Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes. Kurian AW; Ward KC; Abrahamse P; Hamilton AS; Katz SJ JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33426465 [TBL] [Abstract][Full Text] [Related]
34. Novel mutations in actionable breast cancer genes by targeted sequencing in an ethnically homogenous cohort. Akter H; Sultana N; Martuza N; Siddiqua A; Dity NJ; Rahaman MA; Samara B; Sayeed A; Basiruzzaman M; Rahman MM; Rashidul Hoq M; Amin MR; Baqui MA; Woodbury-Smith M; Uddin KMF; Islam SS; Awwal R; Berdiev BK; Uddin M BMC Med Genet; 2019 Sep; 20(1):150. PubMed ID: 31477031 [TBL] [Abstract][Full Text] [Related]
35. Impact of High-to-Moderate Penetrance Genes on Genetic Testing: Looking over Breast Cancer. Turchiano A; Piglionica M; Martino S; Bagnulo R; Garganese A; De Luisi A; Chirulli S; Iacoviello M; Stasi M; Tabaku O; Meneleo E; Capurso M; Crocetta S; Lattarulo S; Krylovska Y; Lastella P; Forleo C; Stella A; Bukvic N; Simone C; Resta N Genes (Basel); 2023 Jul; 14(8):. PubMed ID: 37628581 [TBL] [Abstract][Full Text] [Related]
36. Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge. Bono M; Fanale D; Incorvaia L; Cancelliere D; Fiorino A; Calò V; Dimino A; Filorizzo C; Corsini LR; Brando C; Madonia G; Cucinella A; Scalia R; Barraco N; Guadagni F; Pedone E; Badalamenti G; Russo A; Bazan V ESMO Open; 2021 Aug; 6(4):100235. PubMed ID: 34371384 [TBL] [Abstract][Full Text] [Related]
37. Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. Lee AJ; Cunningham AP; Tischkowitz M; Simard J; Pharoah PD; Easton DF; Antoniou AC Genet Med; 2016 Dec; 18(12):1190-1198. PubMed ID: 27464310 [TBL] [Abstract][Full Text] [Related]
38. Germline genetic variants in men with prostate cancer and one or more additional cancers. Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667 [TBL] [Abstract][Full Text] [Related]
39. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity. Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368 [TBL] [Abstract][Full Text] [Related]
40. High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer. Evans DG; van Veen EM; Byers HJ; Evans SJ; Burghel GJ; Woodward ER; Harkness EF; Eccles DM; Greville-Haygate SL; Ellingford JM; Bowers NL; Pereira M; Wallace AJ; Howell SJ; Howell A; Lalloo F; Newman WG; Smith MJ J Med Genet; 2022 Feb; 59(2):115-121. PubMed ID: 33758026 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]